dapivirine
Trials 37
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-06-26 | Popcouncil | Regulatory Dapivirine Vaginal Ring Recommended as an HIV Prevention Option for Adolescent Girls popcouncil.org ↗
The Population Council is pleased to announce that the monthly dapivirine vaginal ring (DVR) for HIV prevention is now recommended for adolescent girls ages 16 years and older. |
| 2024-10-07 | Popcouncil | Results 3-Month Dapivirine Vaginal Ring for HIV Prevention Demonstrates Superior Drug Release Compared to 1-Month Ring popcouncil.org ↗
The trial found that a 3-month dapivirine vaginal ring delivers the active antiretroviral drug, dapivirine, at higher levels than the 1-month dapivirine vaginal ring. |
| 2022-03-11 | Janssen Research & Development, LLC | Regulatory South Africa Health Products Regulatory Authority Approves Dapivirine Ring Developed by the International Partnership for Microbicides jnj.com ↗
The approval of the dapivirine ring in South Africa is an important step in the decades-long fight against HIV, which is one of the most significant challenges in global health. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-08 | Popcouncil | Dapivirine Vaginal Ring price drops by over 50%, bringing more affordable HIV prevention options to women and adolescent girls in Africa and beyond popcouncil.org ↗ |
| 2025-06-26 | Popcouncil | Dapivirine Vaginal Ring Recommended as an HIV Prevention Option for Adolescent Girls popcouncil.org ↗ |
| 2024-10-07 | Popcouncil | 3-Month Dapivirine Vaginal Ring for HIV Prevention Demonstrates Superior Drug Release Compared to 1-Month Ring popcouncil.org ↗ |
| 2022-03-11 | Janssen Research & Development, LLC | South Africa Health Products Regulatory Authority Approves Dapivirine Ring Developed by the International Partnership for Microbicides jnj.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dapivirine | “We evaluated the acceptability of the 90-day dapivirine levonorgestrel ring (DPV-LNG ring) used for 14 days compared to a dapivirine-only ring (DVR-200mg) in MTN-030/IPM 041 (n...” PMID 39808648 ↗ Jan 202543“containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)” NCT03467347 ↗ “To start, the dapivirine vaginal ring will be included among the other forms of PrEP that are available.” NCT07076043 ↗ “They then underwent 7-day exposure to a ring containing 120 mg of TMC120 (dapivirine).” NCT00700284 ↗ “DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel” NCT05041699 ↗ |
| Known as | [14C]DAPIVIRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL70663 ↗ |
| Known as | AIDS-105293 | ChEMBL registry synonym — accepted as the source's own label CHEMBL70663 ↗ |
| Known as | DAPIRING | “DAPIRING (Dapivirine) 25mg Vaginal Ring” NCT06250504 ↗ |
| Known as | Dapivirina | ChEMBL registry synonym — accepted as the source's own label CHEMBL70663 ↗ |
| Known as | dapivirine gel 4759 | “dapivirine gel 4759, 0.05%, 2.5g applied once daily” NCT00799058 ↗ |
| Known as | Dapivirine Gel 4789 | “A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4789, 0.05%, 2.5g, a Vaginal Microbicide, Conducted...” NCT00917904 ↗1“dapivirine gel 4789, 0.05%, 2.5g applied once daily” NCT00799058 ↗ |
| Known as | DPV | “We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women.” PMID 30289485 ↗ Mar 20196“This study will evaluate the safety and drug detection of the dapivirine (DPV) vaginal ring (VR) and oral Truvada in breastfeeding mother-infant pairs.” NCT04140266 ↗ “Prior trials of a 25 mg dapivirine (DPV) ring have shown a favourable safety profile and approximately 30% risk reduction of HIV-1 infection.” PMID 34118115 ↗ Jun 2021 “containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)” NCT03467347 ↗ “Dapivirine (DPV), formulated as vaginal ring, demonstrated HIV risk reduction.” PMID 34498980 ↗ Dec 2021 “Dapivirine (DPV) is a nonnucleoside reverse transcriptase inhibitor” PMID 24070431 ↗ Oct 2013 “Dapivirine (DPV) Vaginal Ring (VR)” NCT03965923 ↗ |
| Known as | Gel-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL70663 ↗ |
| Known as | R-147681 | ChEMBL registry synonym — accepted as the source's own label CHEMBL70663 ↗ |
| Known as | TMC120 | “candidate microbicide dapivirine (TMC120) for 7 days” NCT00332995 ↗5“pharmacokinetics of dapivirine (TMC120) gel” NCT00304642 ↗ “dapivirine (TMC120) vaginal gel” NCT00304668 ↗ “dapivirine (TMC120) vaginal gel” NCT00303576 ↗ “dapivirine (TMC120) vaginal gel” NCT00309205 ↗ |
| Action | Inhibit | “Dapivirine (DPV) is a nonnucleoside reverse transcriptase inhibitor” PMID 24070431 ↗ Oct 2013 |
| Modality | Small molecule | “Dapivirine (DPV) is a nonnucleoside reverse transcriptase inhibitor” PMID 24070431 ↗ Oct 2013 |
| Route | Other | “intravaginal gel, dosed daily” NCT00613249 ↗ |